Digital healthcare solutions for early risk detection of lung cancer

AstraZeneca

Through our A.Catalyst Network, AstraZeneca partnered with AI solution provider Qure.ai to use their AI platform qXR for detecting incidental lung nodules in routine chest x-rays.

The solution is integrated with medical imaging systems, providing real-time malignancy risk score indicating risk of lung cancer that can be referred for further diagnostics.

The technology has been implemented in 29 countries across 335 sites and has analysed more than 1.5 million chest x-rays (as at December 2023).

As part of our partnership with the World Economic Forum's EDISON Alliance, we have committed to screening five million patients for lung cancer risk using AI technology.